Setting a New Standard in Biosimilars
Alvogen’s sister company, Alvotech, is a fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high-quality biosimilar medicines. They are specialists in biopharmaceutical product creation, all along the value chain from cell line development to commercial manufacturing.
Fully integrated development
Alvotech is focused on developing and bringing to market highest quality biosimilars. The current pipeline consists of biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.
Developement
These products are developed in our four Research & Development centers located across Europe.
Production
High-quality products will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.
Release
Partnership through Alvogen and key global players will be used to bring biosimilars to patients around the world.
In-house research and development
Alvotech is uniquely positioned with a fully integrated R&D and manufacturing engine, driven by best-in-class in-house research and development. Its state-of-the-art manufacturing facility fill finish capacity, situated in a patent-friendly location in Reykjavik, Iceland. Mark Levick leads the Alvotech team with over 400 colleagues who are passionate about transforming patients’ lives and bringing high-quality biopharmaceuticals to market.
